- Home
- / Marinus Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Marinus Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.3
2024-10-29
Market Capitalization
$16 M
2024-10-29
Revenue
$31 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 12, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.3M | 25.5M | 31.0M | |||||||
| Cost of goods sold | 1.5M | |||||||||
| General and administrative expense | 3.2M | 5.5M | 6.2M | 6.7M | 8.8M | 11.5M | 18.5M | 37.3M | 56.8M | 61.2M |
| Operating expense total | 11.9M | 24.4M | 28.3M | 19.0M | 37.2M | 54.4M | 69.7M | 110.8M | 136.8M | |
| EBIT | (11.9M) | (24.4M) | (28.2M) | (19.0M) | (37.2M) | (54.4M) | (67.9M) | (96.9M) | (112.8M) | (131.5M) |
| EBIT margin, % | -442.7% | |||||||||
| Interest income | 12.0K | 64.0K | 128.0K | 324.0K | 454.0K | 354.0K | 499.0K | 80.0K | 2.4M | 8.1M |
| Interest expense | 16.9M | |||||||||
| Pre tax profit | (18.9M) | (36.7M) | (54.1M) | (67.5M) | (98.8M) | (16.4M) | (142.9M) | |||
| Income tax expense | 3.4M | (1.5M) | ||||||||
| Net Income | (10.8M) | (24.8M) | (28.6M) | (18.9M) | (36.7M) | (54.1M) | (67.5M) | (98.8M) | (19.8M) | (141.4M) |
| EPS | (0.5) | (2.0) |